Results 191 to 200 of about 189,252 (309)

Creatinine-to-body weight ratio as an independent predictor of hepatic steatosis severity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study. [PDF]

BMC Gastroenterol
Sun X, Wang X, Younas A, Wang S, Sohail M, Lv J, Huang Z, Liu Y.   +7 more
europepmc   +1 more source

The utility of whole exome sequencing in diagnosing Wilson disease: A case report

JPGN Reports, EarlyView.
Abstract Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene, resulting in toxic copper accumulation in the body. Diagnosis is typically based on biochemistries, including low serum ceruloplasmin and elevated 24‐h urine copper excretion, with Kayser–Fleischer (KF) rings being a supportive ...
Mihir J. Palan, Dana Simpson, Cheryl Miranda, Melanie Hakar, Henry C. Lin   +4 more
wiley   +1 more source

Global molecular landscape of early MASLD progression in human obesity. [PDF]

Elife
Zhao Q, De Nardo W, Wang R, Zhong Y, Keles U, Sakalauskaite G, Zhao LN, Tay H, Youhanna S, Yan M, Xie Y, Kim Y, Lee S, Lim RL, Teo G, Narayanaswamy P, Burton PR, Lauschke VM, Choi H, Watt MJ, Kaldis P.   +20 more
europepmc   +1 more source

Impact of cystic fibrosis transmembrane conductance regulator modulator therapies on liver stiffness and liver enzymes: An observational perspective single‐center cohort study

JPGN Reports, EarlyView.
Abstract Objectives The efficacy of cystic fibrosis transmembrane conductance regulator (CFTR)‐modulator therapies in preventing or ameliorating cystic fibrosis liver disease (CFLD) by correcting CFTR in cholangiocytes is not well‐documented. This study aimed to assess liver function during CFTR‐modulators.
Laura Giugliano, Elisabetta Augustoni, Antonio Pizzol, Anna Opramolla, Cristina Chiadò, Anna Zagaria, Irene Esposito, Giulia Roberto, Alice Ponte, Andrea Evangelista, Paola Quarello, Michele Pinon, Pier Luigi Calvo   +12 more
wiley   +1 more source

Chronic, Environmentally Relevant PM2.5 Exposure Exacerbates Metabolic Dysfunction‐Associated Steatotic Liver Disease and Early‐Stage Renal Dysfunction in a Rodent Model

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT While epidemiological studies link fine particulate matter (PM2.5) exposure to metabolic dysfunction‐associated steatotic liver disease (MASLD) and renal dysfunction, a translational gap exists, as most animal models utilize acute, high‐dose exposures that poorly reflect chronic, moderate‐level human scenarios.
Yi‐Siao Chen, Hugo You‐Hsien Lin, Chien‐Tzu Lin, Si‐Hua Huang, Ming‐Lun Yeh, Ming‐Lung Yu, Jin‐Ching Lee, Yao‐Chi Chung, Wei‐Ming Li, Ching‐Chia Li, Shiu‐Feng Huang, Chia‐Hung Yen   +11 more
wiley   +1 more source

Metabolic dysfunction-associated fatty liver disease: an update. [PDF]

Aust Prescr
O'Halloran R, Adams LA, Deed G, Lubel JS.   +3 more
europepmc   +1 more source

ChREBP refines the hepatic response to fructose to protect the liver from injury [PDF]

, 2017
Angela M. Hall, Brian N. Finck, Hetz, Montgomery   +3 more
core   +3 more sources

Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Patients with chronic hepatitis C (CHC) frequently present with steatotic liver disease (SLD) and cardiometabolic risk factors (CMRFs). This study aimed to evaluate the impact of SLD and CMRFs on liver‐related outcomes (LROs) in CHC patients after HCV eradication.
Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu   +15 more
wiley   +1 more source

Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B. [PDF]

Ann Med
Wang HW, Lai HC, Hsu WF, Chen SH, Kuo YC, Peng CY.   +5 more
europepmc   +1 more source

Efficacy of CPAP Therapy on Liver Steatosis and Insulin Resistance in Fatty Liver Patients With Obstructive Sleep Apnea: A 4‐Year Follow‐Up Cohort Study

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and obstructive sleep apnea (OSA) are comorbid conditions that synergistically increase cardiovascular risk through systemic inflammation and insulin resistance. While continuous positive airway pressure (CPAP) is the standard treatment for OSA, its efficacy in improving hepatic ...
Hsiao‐Chin Shen, Yen‐Hsun Huang, Tzu‐Hao Li, Chih‐Hsun Wu, Yu‐Wei Lee, Hsiao‐Yun Yeh, Hung‐Cheng Tsai, Chien‐Wei Su, Kun‐Ta Chou, Ying‐Ying Yang, Ming‐Chih Hou   +10 more
wiley   +1 more source